Clinical trials: Bronchiectasis Adult
Primary Ciliary Dyskinesia (PCD)
Study of Inhaled RCT1100 in Adults With PCD Caused by Pathogenic Mutations in the DNAI1 Gene to Measure Mucociliary Clearance
This is a multi-dose study with RCT1100 and is designed to provide safety, tolerability and preliminary efficacy data for future clinical studies.
- Trial name
- NCT06633757
- Testing
- RCT1100
- Where
- 3 sites in United States, Denmark and 1 more
- Volunteers
- 14 people
- Sponsor
- ReCode Therapeutics
Bronchiectasis Adult
Airway Clearance and Bronchoalveolar Lavage for Bronchiectasis Patients With Exacerbation
No study have evaluated the efficacy and safety of airway clearance therapy (ACT) and bronchoalveolar lavage (BAL) under bronchoscope for bronchiectasis.
- Trial name
- NCT03643302
- Testing
- Version BF-1T26 electronic bronchoscope
- Where
- China
- Volunteers
- 189 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Bronchiectasis Adult
The C-BRIDGE Study: China Bronchiectasis Research Involving Databases, Genomics, and Endotyping
Bronchiectasis is a heterogeneous airway disease with diverse causes, making precise diagnosis, prognosis, and treatment response prediction challenging.
- Trial name
- NCT06900062
- Where
- 9 sites in China
- Volunteers
- 1,500 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Bronchiectasis Adult, Bronchiectasis With Acute Exacerbation
Airway Clearance by Fiberoptic Bronchoscopy in Bronchiectasis Followed by Gentamicin and Dexamethason Injection
Fiberoptic Bronchoscopic Removal of Secretions and Antibiotic Injection
- Trial name
- NCT06906354
- Testing
- Airway Clearance by Fiberoptic Bronchoscopy in Bronchiectasis Followed by Gentamicin and Dexamethason Injection
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Alexandria University
Bronchiectasis
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Inhaled CHF6333 After Single Doses in Healthy Volunteers and After Single and Repeated Doses in Subjects With Bronchiectasis
The aim of this clinical trial is to assess the safety of: single doses of the study drug CHF6333 in Healthy Volunteers (HVs) and in subjects with Bronchiectasis (BE) - Part I repeated doses of the study drug CHF6333 in subjects…
- Trial name
- NCT06166056
- Testing
- CHF6333
- Where
- 8 sites in United Kingdom
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Chiesi Farmaceutici S.p.A.
COVID, Pneumonia, Viral
Lung Damage Caused by SARS-CoV-2 Pneumonia (COVID-19)
Pneumonia is a recurrent element of COVID-19 infection, it is often associated with development of respiratory failure and patients frequently need various degrees of oxygen therapy up to non invasive ventilation (NIV-CPAP) and…
- Conditions
- COVID, Pneumonia, Viral, Barotrauma, Interstitial Lung Disease
- Trial name
- SequelaeCov (NCT04435327)
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- University of Milano Bicocca
Bronchiectasis Adult, Bronchiectasis With Pseudomonas Aeruginosa Colonization
First in Human Trial of CTX-187 in Healthy Volunteers and Chronically Infected Patients
The primary objective of this trial is to assess the safety and tolerability of single and multiple ascending intravenously (IV) infused doses of CTX-187 when administered to healthy adult male and female participants and…
- Conditions
- Bronchiectasis Adult, Bronchiectasis With Pseudomonas Aeruginosa Colonization, Bacterial Infections
- Trial name
- NCT07708116
- Testing
- CTX-187
- Where
- Netherlands
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Centauri Therapeutics Limited
Bronchiectasis
Comparison of Two Antibiotic Regimens for the Treatment of Early Airways Infection With PA in Adults With Bronchiectasis
Chronic airways infection with Pseudomonas aeruginosa (PA) is associated with increased frequency of exacerbations, deterioration in quality of life and increased mortality in adult patients with bronchiectasis.
- Trial name
- ANTEIPA (NCT06368804)
- Testing
- Antibiotic monotherapy treatment and follow-up, Antibiotic bitherapy treatment and follow-up
- Where
- 18 sites in France
- Volunteers
- 196 people
- Sponsor
- Centre Hospitalier Intercommunal Creteil
Bronchiectasis Adult
The BRIDGE Study - Bronchiectasis Research Involving Databases, Genomics and Endotyping
Bronchiectasis is a complex heterogeneous disorder. Treatment is challenging and many recent randomized controlled trials have been negative.
- Trial name
- BRIDGE (NCT03791086)
- Where
- United Kingdom
- Volunteers
- 1,000 people
- Sponsor
- University of Dundee
Cystic Fibrosis, Bronchiectasis
A Study to Test How Well BI 1291583 is Tolerated by People With Cystic Fibrosis Bronchiectasis (Clairafly™)
This study is open to adults aged 18 years and older with cystic fibrosis bronchiectasis. The purpose of this study is to find out whether a medicine called BI 1291583 is tolerated by people with cystic fibrosis bronchiectasis.
- Trial name
- NCT05865886
- Testing
- BI 1291583
- Where
- 24 sites in United States, Belgium and 5 more
- Volunteers
- 22 people
- Sponsor
- Boehringer Ingelheim
Bronchiectasis Adult
Benefits of Inhalation of Hypertonic Saline Solution Prior to Physiotherapy ELTGOL Technique in Bronchiectasis
Bronchiectasis is a chronic bronchial disease in which the usual capacity to remove secretions does not function correctly, causing mucus retention that leads to chronic infection.
- Trial name
- NCT06443658
- Testing
- Hypertonic saline, Isotonic saline, ELTGOL
- Where
- Spain
- Volunteers
- 57 people
- Sponsor
- Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta
Bronchiectasis Adult, Bronchiectasis With Acute Exacerbation
Exploring How Viral Infections Affect People With Chronic Lung Disease
Many people with chronic lung disease have disease flare-ups. It was previously believed that these were mainly caused by bacteria but recent evidence suggests that viruses could be an important trigger.
- Conditions
- Bronchiectasis Adult, Bronchiectasis With Acute Exacerbation, COPD (Chronic Obstructive Pulmonary Disease), Respiratory Infection Virus
- Trial name
- PRIVILEGE (NCT06625944)
- Where
- United Kingdom
- Volunteers
- 180 people
- Sponsor
- Imperial College London
Bronchiectasis
Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis
The AIR-BX2 study enrolled people with non-cystic fibrosis (non-CF) bronchiectasis and gram-negative airway infection. Participants received two 28-day courses of either Aztreonam for Inhalation Solution (AZLI) or placebo taken 3…
- Trial name
- AIR-BX2 (NCT01314716)
- Testing
- AZLI
- Where
- 85 sites in United States, Australia and 8 more
- Volunteers
- 274 people
- Sponsor
- Gilead Sciences
Healthy Participants, Non-cystic Fibrosis Bronchiectasis
A Phase 1a/1b Study to Investigate the Safety, Tolerability, Microbiological Response, and Pharmacokinetics of Inhaled Rev-56 in Adult Healthy Volunteers and Adult Non-cystic Fibrosis Bronchiectasis (NCFB) Patients With Chronic P. Aeruginosa
This is a Phase 1a/1b study to test the safety, tolerability, microbiological response, and pharmacokinetics of inhaled Rev-56 compared to placebo in adult healthy participants and non-cystic fibrosis bronchiectasis (NCFB)…
- Trial name
- NCT07709494
- Testing
- Rev-56 for Inhalation
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Revagenix, Inc.
Bronchiectasis Adult, Bronchiectasis With Acute Exacerbation
A Rhinovirus Challenge Study to Investigate Exacerbations and Immune Responses in Bronchiectasis
The goal of this study is to determine if viral infection with the common cold leads to an exacerbation in participants with bronchiectasis.
- Conditions
- Bronchiectasis Adult, Bronchiectasis With Acute Exacerbation, Bronchiectasis With Chronic Infection With Pseudomonas Aeruginosa, Viral Infection
- Trial name
- BARRIER (NCT06931002)
- Testing
- Rhinovirus A-16 Infection
- Where
- United Kingdom
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Cancer, COPD
SELF-BREATHE RCT for Chronic Breathlessness
A feasibility RCT comprising two groups: 1. Intervention (SELF-BREATHE in addition to standard NHS care) 2. Control group (standard / currently available NHS care)
- Conditions
- Cancer, COPD, Asthma, Bronchiectasis Adult
- Trial name
- NCT04574050
- Testing
- SELF-BREATHE
- Where
- United Kingdom
- Volunteers
- 52 people
- Sponsor
- King's College Hospital NHS Trust
Bronchiectasis Adult
Long-term Impact of Inhaled Tobramycin for Pseudomonas Aeruginosa Eradication in Bronchiectasis (ERASE II)
The ERASE II study is a prospective follow-up study designed to assess the long-term impact of successful eradication of Pseudomonas aeruginosa (PA) in patients with bronchiectasis.
- Trial name
- NCT06760273
- Testing
- No Intervention: Observational Cohort
- Where
- 58 sites in China
- Volunteers
- 364 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Cystic Fibrosis, Bronchiectasis Adult
Bacille Calmette-Guerin (BCG) Vaccine for Immune Protection Against Infections
This is pilot study of the immunologic effects of intradermal Bacille Calmette-Guerin (BCG) vaccination of adults with cystic fibrosis (CF), non-CF bronchiectasis (NCFB), and healthy volunteers.
- Conditions
- Cystic Fibrosis, Bronchiectasis Adult, Non-Tuberculous Mycobacteria
- Trial name
- NCT04884308
- Testing
- BCG TICE Vaccine
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Copd, COPD Exacerbation
Telehealth and Onsite Maintenance Exercise in Chronic Lung Disease
The goal of this pilot clinical trial is to compare telehealth and onsite supervised maintenance exercise program for adults with Chronic Lung Disease.
- Conditions
- Copd, COPD Exacerbation, COPD Bronchitis, Emphysema or COPD
- Trial name
- CLD (NCT06304207)
- Testing
- Onsite Maintenance Exercise Training, Telehealth Maintenance Exercise
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- MGH Institute of Health Professions
Bronchiectasis Adult, Pseudomonas Infections
Tobramycin in Bronchiectasis Colonized With Pseudmonas Aeruginosa
This is a phase 3 study. Patients will be enrolled from 14 medical centers in mainland China. Eligible patients will be randomly allocated to treatment group (tobramycin nebulization, 300mg bid) and control group (natural saline…
- Trial name
- TORNASOL (NCT03715322)
- Testing
- Tobramycin Inhalant Product, usual care, Natural saline inhalation
- Where
- China
- Volunteers
- 350 people
- Sponsor
- Guangzhou Institute of Respiratory Disease